These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 26093227)
21. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108 [TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204 [TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis. Virgilio E; Vecchio D; Crespi I; Serino R; Cantello R; Dianzani U; Comi C Mult Scler Relat Disord; 2021 Nov; 56():103231. PubMed ID: 34492629 [TBL] [Abstract][Full Text] [Related]
24. Gray matter atrophy in multiple sclerosis: a longitudinal study. Fisher E; Lee JC; Nakamura K; Rudick RA Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561 [TBL] [Abstract][Full Text] [Related]
25. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842 [TBL] [Abstract][Full Text] [Related]
26. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. Rostasy K; Withut E; Pohl D; Lange P; Ciesielcyk B; Diem R; Gärtner J; Otto M J Child Neurol; 2005 Oct; 20(10):822-5. PubMed ID: 16417878 [TBL] [Abstract][Full Text] [Related]
28. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Checa A; Khademi M; Sar DG; Haeggström JZ; Lundberg JO; Piehl F; Olsson T; Wheelock CE Mult Scler; 2015 Sep; 21(10):1271-9. PubMed ID: 25480867 [TBL] [Abstract][Full Text] [Related]
29. Elevation of tau protein levels in the cerebrospinal fluid of children with West syndrome. Inoue H; Matsushige T; Hasegawa S; Abe A; Iida Y; Inoue T; Ichiyama T Epilepsy Res; 2012 Nov; 102(1-2):8-12. PubMed ID: 22831649 [TBL] [Abstract][Full Text] [Related]
30. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Hein Née Maier K; Köhler A; Diem R; Sättler MB; Demmer I; Lange P; Bähr M; Otto M Neurosci Lett; 2008 May; 436(1):72-6. PubMed ID: 18359164 [TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Paladino P; Valentino F; Piccoli T; Piccoli F; La Bella V Eur J Neurol; 2009 Feb; 16(2):257-61. PubMed ID: 19138331 [TBL] [Abstract][Full Text] [Related]
32. Increased cerebrospinal fluid cleaved tau protein (C-tau) levels suggest axonal damage in pediatric patients with brain tumors. Cengiz P; Zemlan F; Eickhoff JC; Ellenbogen R; Zimmerman JJ Childs Nerv Syst; 2015 Aug; 31(8):1313-9. PubMed ID: 25899850 [TBL] [Abstract][Full Text] [Related]
34. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. Bartosik-Psujek H; Stelmasiak Z J Neural Transm (Vienna); 2006 Mar; 113(3):339-45. PubMed ID: 15997419 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid derived from progressive multiple sclerosis patients promotes neuronal and oligodendroglial differentiation of human neural precursor cells in vitro. Cristofanilli M; Cymring B; Lu A; Rosenthal H; Sadiq SA Neuroscience; 2013 Oct; 250():614-21. PubMed ID: 23876320 [TBL] [Abstract][Full Text] [Related]
36. Tau protein in the cerebrospinal fluid is a marker of brain injury after aortic surgery. Shiiya N; Kunihara T; Miyatake T; Matsuzaki K; Yasuda K Ann Thorac Surg; 2004 Jun; 77(6):2034-8. PubMed ID: 15172260 [TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1. Peric S; Mandic-Stojmenovic G; Markovic I; Stefanova E; Ilic V; Parojcic A; Misirlic-Dencic S; Ostojic M; Rakocevic-Stojanovic V; Kostic V Eur J Neurol; 2014 Feb; 21(2):231-7. PubMed ID: 23834502 [TBL] [Abstract][Full Text] [Related]
39. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry. Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944 [TBL] [Abstract][Full Text] [Related]
40. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]